《COVID-19檢測》很害! Bodyspher兩分鐘血液檢測還沒得到FDA核准 公司被罵翻

秒速閱讀: 台灣不少公司也宣稱擁有新冠肺炎病毒檢測,且所需結果的時間只有十分鐘、十五分鐘等等,投資人都需要謹慎閱讀報導,尤其檢測出來的準確率有多高都需要了解。

就在FDA公布Cellex公司獲得首個新冠肺炎病毒抗體檢測核准時(需要15分鐘),總部位於洛杉磯的Bodysphere上周二宣布已獲得緊急使用授權(EUA),用於快速COVID-19血清學測試,能夠在短短兩分鐘內得出結果,同時被媒體解讀為這種簡單測試可以讓自己了解是否應該自我隔離。

延伸閱讀: 《COVID-19檢測》FDA核准首個抗體檢測病毒之緊急使用 Cellex抗體測試只需抽血15-20分鐘得出結果 但只限和授權試驗室

媒體還報導,公司已將數百萬獲得聯邦政府的緊急授權使用的檢測試劑送上貨機準備運送到各地

但最新的資訊顯示,該公司的檢測並沒有得到FDA的核准。該公司本身已經發布了其首席執行官Charlton E. Lui的聲明,稱媒體對Bodysphere的檢測有所誤解。聯邦機構也警告人們不要試圖兜售欺詐性的冠狀病毒檢測、疫苗、藥物和醫療設備。

還在等待FDA的核准....

BODYSPHERE的首席執行官Charlton E. Lui
發表了以下澄清聲明:

急於將急需的測試套件帶到第一線,BODYSPHERE以為當製造商的產品在FDA註冊網站上列出時,即表示食品和藥物管理局(FDA核准了緊急使用授權(EUA。......(以下為公司澄清稿)

“In the rush to get the desperately needed test kits to the front lines, BODYSPHERE believed when the manufacturer’s product was listed on the FDA Registry website, that was the Food and Drug Administration’s (FDA) notification the Emergency Use Authorization (EUA) was issued. This misunderstanding does not in any way invalidate the test kits authenticity or effectiveness. Under the FDA policy, upon the manufacturer receiving its acknowledgement letter (attached) from the FDA, BODYSPHERE being named the distributor on the EUA submission, was authorized to market and distribute test kits to any licensed healthcare practitioner in the United States for diagnostic use while the manufacturer awaits word of a final decision on its FDA EUA application. The manufacturer has performed clinical trials and the information from those trials will be made available to any healthcare provider or government official seeking to validate the effectiveness and authenticity of these tests.”

Additionally, yesterday the phone lines were overwhelmed from calls around the world seeking to acquire these tests. BODYSPHERE is adding new phone lines that will be up and running ASAP to accommodate the influx of calls. BODYSPHERE is anxiously awaiting the FDA’s issuance of the EUA to the manufacturer.

喜歡這篇文章嗎?立即分享

你可能感興趣的文章